What Is Peptide Therapy? A Complete Guide

Key Takeaways

• Regulatory Status: Peptide therapies range from FDA-approved medications (semaglutide, tirzepatide, tesamorelin, insulin) to compounded formulations available by prescription (sermorelin, CJC-1295/ipamorelin) to unapproved research compounds (BPC-157, TB-500). As of April 2026, several previously compounded peptides are classified as FDA Category 2 bulk drug substances, restricting their compounding. Status varies by specific compound — see individual compound pages.
• Research Stage: FDA-approved peptide therapies have robust Phase 3 clinical trial data; compounded formulations have established clinical data for primary indications; research-grade compounds have primarily preclinical or limited early human data.
• Availability: Prescription only. FDA-approved compounds are available through licensed prescribers and pharmacies. Compounded formulations require a prescription from a licensed provider working with a licensed 503A compounding pharmacy.
• How it works: Peptide therapies bind specific receptors to trigger targeted biological signaling cascades in the body.
• What the evidence shows: In individual clinical trials, semaglutide 2.4 mg weekly produced approximately 14.9% mean weight reduction and tirzepatide 15 mg weekly produced approximately 21% mean weight reduction over 68–72 weeks. Growth hormone secretagogue therapy has smaller and less rigorous evidence bases for body composition outcomes in adults without documented GH deficiency.

Peptide therapeutics have been part of mainstream medicine for over a century. Insulin — a 51-amino-acid peptide — has been in clinical use since 1921 and remains among the most widely-prescribed biologics in the U.S. today. A 2018 review by Lau and Dunn, published in Bioorganic and Medicinal Chemistry, catalogued more than 60 FDA-approved peptide drugs and over 150 compounds in active clinical development; the THPdb2 database (2024) expanded this count to 85 FDA-approved peptide and polypeptide therapeutics as of 2024. What is newer is the direct-to-consumer market for compounded and research-grade peptides that has grown around that clinical foundation — a market where evidence quality ranges from decades of randomized controlled trial data to single rodent studies. The distinction matters before any therapy decision is made.

How Peptide Therapy Works in the Body

Receptor binding and signal transduction

Peptide therapies work by binding to specific receptors on cell surfaces — most commonly G protein-coupled receptors (GPCRs) — and activating intracellular signaling cascades. Because peptide sequences are structurally precise, their receptor binding is highly targeted. A 2022 review by Wang and colleagues, published in Signal Transduction and Targeted Therapy, provided a comprehensive overview of how peptide drug design leverages receptor specificity across therapeutic categories from metabolic disease to oncology. That receptor specificity is what allows GLP-1 receptor agonists to enhance insulin secretion without causing hypoglycemia at normal glucose levels: the receptor's downstream signaling is glucose-dependent. It is also what gives growth hormone secretagogues their ability to stimulate pulsatile GH release without the continuous suppressive effect of exogenous HGH.

Why most therapeutic peptides require injection

Most peptides are degraded by digestive enzymes before reaching systemic circulation, which is why subcutaneous injection is the dominant delivery route for therapeutic compounds. A 2015 review by Fosgerau and Hoffmann, published in Drug Discovery Today, established injection as the standard delivery route for most therapeutic peptides due to first-pass metabolic degradation. Engineering solutions including PEGylation, cyclization, and non-natural amino acid substitution have extended half-lives substantially; a 2018 review by Henninot, Collins, and Nuss in Bioorganic and Medicinal Chemistry catalogued the chemical-modification toolkit that has made peptides progressively more drug-like. Oral delivery has been achieved for semaglutide through a SNAC permeation enhancer technology, as documented in a 2022 review by Aroda and colleagues in Reviews in Endocrine and Metabolic Disorders, documenting oral semaglutide's pharmacokinetics and clinical bioavailability.

GLP-1 receptor agonist mechanism

GLP-1 receptor agonists — the class that includes semaglutide and tirzepatide — mimic the action of endogenous glucagon-like peptide-1, an incretin hormone produced in intestinal L-cells after eating. A 2025 review by Moiz and colleagues, published in the American Journal of Medicine, reviewed the central and peripheral mechanisms by which GLP-1 receptor agonists produce weight loss: suppression of appetite through hypothalamic GLP-1 receptors, delayed gastric emptying, reduced hedonic eating drive, and glucose-dependent insulin secretion in the pancreas. Tirzepatide adds a second mechanism through GIP (glucose-dependent insulinotropic polypeptide) receptor agonism, which augments both the metabolic and appetite-suppression effects observed with GLP-1 agonism alone.

Growth hormone secretagogue mechanism

Growth hormone secretagogues — including sermorelin, CJC-1295, and ipamorelin — stimulate the pituitary gland to release its own growth hormone in pulses that approximate natural physiological rhythms. A 1998 study by Raun and colleagues, published in the European Journal of Endocrinology, characterized ipamorelin as the first highly selective growth hormone secretagogue that stimulates GH release without meaningfully elevating cortisol or ACTH — a selectivity profile that distinguishes secretagogues from older GH-releasing compounds. The downstream signal is IGF-1, produced primarily in the liver in response to GH pulses. This GH-IGF-1 axis activity is the mechanistic basis for the body composition changes — such as lean mass and visceral fat — that have been proposed for this compound class. Adequately powered trials in adults without documented GH deficiency have not been published.

Who Is a Candidate for Peptide Therapy?

Who providers typically evaluate for this therapy

Providers typically consider peptide therapy for individuals who meet defined clinical criteria based on the specific compound under consideration. No single candidacy profile applies to the full category.

• GLP-1 receptor agonists (semaglutide, tirzepatide): Adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia — consistent with the enrollment criteria from the STEP and SURMOUNT trial programs.
• Growth hormone secretagogues (sermorelin, CJC-1295/ipamorelin): Compounded, off-label use. Candidacy and appropriateness are determined by a licensed clinician based on individual history, labs, and differential diagnosis. Symptoms such as fatigue and changes in body composition have many possible causes and do not on their own indicate a need for GH secretagogue therapy.
• Tesamorelin: FDA approval is specific to HIV-associated lipodystrophy. Tesamorelin has not been evaluated in adequate and well-controlled trials for other indications; off-label use outside the HIV-lipodystrophy population is not supported by the FDA-approved labeling.
• Tissue repair peptides (BPC-157, TB-500): As of April 2026, both are classified as FDA Category 2 bulk drug substances, restricting their compounding. Human evidence is primarily preclinical; use outside an IRB-approved research context is not supported by the current evidence base.

Candidacy assessment includes reviewing health history, current medications, and relevant baseline labs.

Who should not use this therapy

Based on the mechanisms of specific compound classes, the following groups face elevated risk or are typically excluded from peptide therapy protocols. This is not an exhaustive list for any specific compound; a licensed provider evaluates individual risk factors, medication interactions, and lab values before prescribing.

• Active or suspected malignancy: Growth hormone secretagogue therapy may theoretically support IGF-1-driven proliferative signaling. Use in patients with active or suspected malignancy requires careful provider evaluation and is generally avoided without specialist consultation.
• Pregnancy and breastfeeding: No adequate reproductive safety data exist for most peptide therapies. GLP-1 receptor agonists should be discontinued before planned pregnancy per FDA labeling.
• Type 1 diabetes (for GH secretagogues): GH stimulation can impair insulin sensitivity; close glucose monitoring is required if prescribed in this context.
• Medullary thyroid carcinoma or MEN2 (for GLP-1 agonists): FDA labeling for GLP-1 receptor agonists contraindicates use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, based on rodent carcinogenicity data.
• Severe renal impairment: Renal clearance affects peptide metabolism; eGFR should be established before prescribing injectable peptides, particularly at therapeutic doses.
• Pancreatitis history (for GLP-1 agonists): GLP-1 agonists are associated with a small increased risk of pancreatitis; prior pancreatitis history warrants careful provider assessment.

Peptide Therapy and the Evidence: What the Research Actually Shows

GLP-1 receptor agonists for weight management and cardiovascular outcomes [Human RCT — FDA-approved indication]

Among weight-management peptide therapies, semaglutide 2.4 mg weekly has the most robust human evidence. In the STEP 1 trial, published by Wilding and colleagues in the New England Journal of Medicine in 2021, 1,961 adults with obesity or overweight and at least one comorbidity received weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. Participants in the semaglutide group achieved a mean body weight reduction of 14.9% compared with 2.4% in the placebo group; 86.4% of semaglutide recipients lost at least 5% of body weight, compared with 31.5% in the placebo group. The SELECT trial, published by Lincoff and colleagues in the New England Journal of Medicine in 2023, extended the evidence to hard cardiovascular endpoints: semaglutide reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.72–0.90) in 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, over a median of 33 months. Based on SELECT, FDA approved a new indication for Wegovy in March 2024 to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight — the first on-label cardiovascular-outcomes indication for any GLP-1 receptor agonist. Tirzepatide, the dual GIP/GLP-1 receptor agonist approved as Mounjaro and Zepbound, achieved approximately 21% mean weight loss at 15 mg over 72 weeks versus approximately 3% with placebo in the SURMOUNT-1 trial, published by Jastreboff and colleagues in the New England Journal of Medicine in 2022, enrolling 2,539 adults without diabetes.

Tesamorelin for visceral adipose tissue reduction [Human RCT — FDA-approved indication]

Tesamorelin, a stabilized GHRH analog FDA-approved as Egrifta, has the strongest evidence among growth hormone-axis peptides for a defined indication. Stanley and colleagues, in a randomized controlled trial published in JAMA in 2014, enrolled 311 HIV-infected adults with central adiposity; tesamorelin significantly reduced visceral adipose tissue by a mean of 34 cm² versus a nonsignificant 8 cm² increase on placebo over 6 months (net treatment effect −42 cm², 95% CI −71 to −14, P = 0.005) and reduced liver fat in those with hepatic steatosis. Tesamorelin is a 44-amino-acid synthetic peptide. Under the March 23, 2020 "deemed to be a license" transition provision of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), peptides greater than 40 amino acids that had been approved under NDAs were transitioned to biologics license applications. As a result, tesamorelin is now regulated as a biologic and cannot be lawfully compounded under Section 503A — only the FDA-approved Egrifta product is legally available in the U.S. This 40-amino-acid threshold is also why shorter GHRH-class peptides like sermorelin (29 aa), CJC-1295 (30 aa), and ipamorelin (5 aa) remain subject to the 503A compounding framework, not the biologics framework. Its use outside the HIV-lipodystrophy indication is off-label and has not been evaluated in adequate and well-controlled clinical trials for other populations.

Growth hormone secretagogues: sermorelin and CJC-1295/ipamorelin [Limited human data — compounded, off-label]

Sermorelin and the CJC-1295/ipamorelin combination are available by prescription through licensed 503A compounding pharmacies for off-label body composition and GH-axis support applications. Ipamorelin's pharmacokinetics in healthy human volunteers were first characterized by Gobburu and colleagues, published in Pharmaceutical Research in 1999, establishing ipamorelin's dose-proportional GH release and favorable selectivity profile compared with earlier secretagogue compounds. Adequately powered Phase 3 trials for these compounds in the specific populations currently using them (adults without documented GH deficiency, seeking body composition improvement) have not been published. Clinical evidence for off-label body composition applications is drawn from smaller and earlier studies. Any off-label use reflects the independent clinical judgment of the prescribing physician and has not been evaluated or endorsed by the FDA.

BPC-157 and TB-500 for tissue repair [Animal model — not FDA-approved]

BPC-157 and TB-500 (thymosin beta-4 fragment) have been studied in animal models for soft tissue healing, inflammation, and musculoskeletal repair. A 2019 review by Gwyer and colleagues, published in Cell and Tissue Research, reviewed BPC-157 preclinical data in musculoskeletal soft tissue healing, noting that most evidence derives from animal models and human clinical data are limited. A 2026 systematic review by Vasireddi and colleagues, published in HSS Journal, described BPC-157's proposed mechanism in orthopaedic sports medicine while concluding that FDA approval is absent and that human data remain limited. As of April 2026, both BPC-157 and TB-500 are classified as FDA Category 2 bulk drug substances; their compounding is restricted pending further FDA review. Use outside an IRB-approved clinical research study is not supported by the available evidence. [Animal model only]

Delivery Methods for Peptide Therapy

Subcutaneous injection

Most therapeutic peptides are administered by subcutaneous injection — delivered into the fatty tissue just below the skin. This route provides reliable absorption into the bloodstream while preserving the peptide's structural integrity, which oral delivery typically degrades. Subcutaneous injection achieves consistent pharmacokinetics across injection sites including the abdomen, upper thigh, and outer upper arm. In the STEP 1 and SURMOUNT-1 trials, participants self-administered weekly subcutaneous injections at home following initial provider instruction. A 2016 global consensus recommendation by Frid and colleagues, published in Mayo Clinic Proceedings, established best-practice subcutaneous injection technique from 183 diabetes experts, including site rotation and needle-length guidance applicable to peptide injections broadly.

Oral formulations

Oral peptide delivery has historically been limited by enzymatic degradation in the gastrointestinal tract before systemic absorption. Oral semaglutide has been developed in multiple formulations: Rybelsus (3 mg, 7 mg, and 14 mg oral tablet, FDA-approved for type 2 diabetes in September 2019); and a higher-dose oral semaglutide formulation approved in April 2025 for chronic weight management. Both use a SNAC permeation enhancer that facilitates absorption across the gastric mucosa, as documented in Aroda and colleagues' 2022 review. As a practical matter, most compounded peptides are not bioavailable by oral route and require injection for therapeutic effect. Oral formulations marketed online for research peptides should not be presumed to have the same pharmacokinetics as injected formulations of the same compound.

Nasal spray

A subset of peptide therapies has been studied or used in intranasal formulations. Bremelanotide (PT-141), FDA-approved as Vyleesi (subcutaneous auto-injector) for premenopausal women with hypoactive sexual desire disorder in June 2019, is occasionally compounded in intranasal formulations by some providers. Such compounding depends on the bulk drug substance's status under § 503A(b)(1)(A)(i) (USP monograph, component of an FDA-approved drug, or placement on the 503A Bulks List) and is not supported by FDA-approved intranasal labeling. Compounded intranasal formulations are off-label and their pharmacokinetics differ from the approved subcutaneous route. Nasal delivery bypasses first-pass hepatic metabolism but tends to produce more variable absorption than subcutaneous injection for most peptide classes due to mucosal variability and limited surface area. Most growth hormone secretagogues and metabolic peptides lack clinical evidence for intranasal delivery as a primary route.

Topical and other routes

Topical peptide formulations are cosmetic products regulated under FDA cosmetics law, not as drugs. They work at the skin surface and are not evaluated by the FDA for systemic therapeutic effects. Intravenous infusion is not a standard route for peptide therapies; most peptide administration is subcutaneous. Some clinics offer compounded IV formulations of non-peptide compounds (such as NAD+) in supervised settings — these are not peptide therapies and fall outside the scope of this article. Intramuscular injection is used for some compounds but is less common than subcutaneous for most peptide-therapy applications.

Safety and Side Effects

Side effect profiles vary significantly across the peptide therapy category — from well-characterized safety profiles in FDA-approved compounds to largely unknown profiles in research-grade compounds. The information below reflects compound-class patterns; individual response varies.

Common side effects (typically mild to moderate, dose-dependent):

• Nausea, vomiting, diarrhea, and constipation — most common with GLP-1 receptor agonists; dose-dependent and typically most pronounced during dose escalation; usually resolves or becomes manageable over 4 to 8 weeks
• Injection site reactions (redness, swelling, bruising, mild pain) — subcutaneous administration; most common in initial weeks of therapy and typically self-limiting with proper site rotation
• Transient headache or mild fatigue, particularly in the first 1 to 2 weeks of a new therapy or dose increase
• Water retention or transient peripheral edema — associated with GH-stimulating peptides at higher doses; generally resolves with dose adjustment
• Reduced appetite, particularly with GLP-1 receptor agonists — a mechanism-based effect, not a pathological side effect in the weight-management context, but relevant for monitoring nutritional adequacy

Less common but clinically important:

• Cholelithiasis (gallstone formation) — a meta-analysis by He and colleagues, published in JAMA Internal Medicine in 2022, found GLP-1 receptor agonists are associated with increased gallbladder and biliary disease risk at higher doses and longer durations across 76 randomized controlled trials
• IGF-1 elevation above reference range — observed with growth hormone secretagogue therapy in clinical practice; quantitative dose-response data for compounded GH secretagogues (sermorelin, CJC-1295, ipamorelin) in adults without documented GH deficiency are limited, so IGF-1 monitoring at baseline and during therapy is the recommended approach
• Impaired glucose tolerance — documented with GH-axis peptides through GH-induced insulin resistance; fasting glucose and HbA1c monitoring during GH-secretagogue therapy is standard clinical practice
• Lean mass loss during aggressive weight-loss peptide therapy — a 2024 review by Locatelli and colleagues, published in Diabetes Care, characterized incretin-based pharmacotherapy as producing significant lean mass reduction and recommended supervised resistance exercise and protein monitoring as mitigation strategies — as a clinical-practice recommendation from the review authors, not as FDA-labeled guidance
• Immunogenic reactions — injectable peptides can elicit anti-drug antibody formation in some patients; monitoring for signs of injection-site hypersensitivity is part of standard follow-up

Risks specific to compounded and unregulated sources:

• Contamination and dosing inconsistency — a 2013 review by Gudeman and colleagues, published in Drugs in R&D, documented that compounded drugs lack FDA premarket approval and have higher failure and contamination rates than FDA-approved products; risks are highest with gray-market sources not subject to any pharmacy regulation
• Infectious risk — a 2013 analysis by Staes and colleagues, published in the American Journal of Health-System Pharmacy, documented 11 infectious outbreaks from compounding pharmacies between 2000 and 2012 involving 207 patients and 17 deaths, data that preceded and helped motivate the November 2013 Drug Quality and Security Act — which created the modern § 503A / § 503B compounding regulatory architecture. This pre-DQSA outbreak history is why current 503A compliance, § 503B oversight, and pharmacy quality standards matter when evaluating a peptide provider

When to contact your provider:

• Persistent injection site pain, hardening, warmth, spreading redness, or fever (signs of infection)
• Severe or persistent nausea, vomiting, or abdominal pain — particularly upper abdominal pain that may suggest pancreatitis
• Any cardiovascular symptoms — chest pain, shortness of breath, palpitations — during therapy
• Signs of hypoglycemia in patients with metabolic conditions on concurrent medications
• Significant joint pain or severe water retention not resolving with dose adjustment

Side effects are typically managed through dose adjustment under the supervision of a licensed provider. The risk profile of any specific compound should be reviewed with a prescribing clinician before starting.

What to Test Before Starting Peptide Therapy

Establishing a baseline before starting any peptide therapy gives both the patient and provider interpretable reference points — not just for beginning therapy, but for assessing response over time and identifying any adverse signals early.

• IGF-1: The primary downstream marker of growth hormone axis activity. Monitoring IGF-1 at baseline establishes whether the GH axis is functioning normally and provides the essential reference point for anyone starting a growth hormone secretagogue. For GLP-1 therapies, baseline IGF-1 provides general metabolic context.
• Fasting glucose: Core metabolic marker relevant to any compound that intersects with insulin sensitivity. A baseline fasting glucose characterizes pre-treatment metabolic status and enables interpretation of any glycemic changes during therapy.
• HbA1c: The 3-month average of blood glucose. The primary efficacy endpoint in most metabolic peptide clinical trials including the STEP and SURMOUNT trial programs. A baseline HbA1c makes any subsequent metabolic change interpretable.
• Fasting insulin: Together with fasting glucose, characterizes insulin resistance. Particularly relevant before GLP-1 agonist or GH-secretagogue therapy. Baseline fasting insulin establishes the degree of insulin sensitivity before any metabolic intervention.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides): GLP-1 agonists are associated with cholelithiasis risk and lipid changes. A pre-treatment triglyceride and lipid baseline supports interpretation of any subsequent changes.
• eGFR and creatinine: Renal clearance affects peptide pharmacokinetics and dose adjustment. An eGFR baseline is part of standard pre-treatment assessment for injectable peptide protocols.
• Liver enzymes (GGT, ALT): Hepatic function baseline for compounds with hepatic processing. Changes in GGT and ALT can signal hepatocellular stress. Fourman and colleagues documented that tesamorelin-induced visceral fat reduction is associated with improved liver enzymes, published in AIDS in 2017, underscoring hepatic monitoring as both a safety and efficacy signal.
• hs-CRP: Systemic inflammation marker relevant for peptides studied in anti-inflammatory or tissue-repair contexts. Baseline high-sensitivity CRP provides reference context for any inflammatory changes during therapy.

Establishing these markers before beginning any peptide therapy is covered in depth in Superpower's metabolic health biomarker testing guide. For growth hormone secretagogue therapy specifically, IGF-1, fasting glucose, and HbA1c are the most informative pre-treatment markers; for GLP-1 therapy, HbA1c, fasting glucose, insulin, and lipid panel form the core baseline.

What Your Labs May Show During Peptide Therapy

Providers typically monitor specific biomarker directions to assess whether a therapy is producing its intended effect and to identify adverse signals early. For GLP-1 receptor agonist therapy, data consistent with therapeutic response include decreasing HbA1c and fasting glucose, improving lipid parameters, and — in high-risk patients — blood pressure trending toward target. In the SELECT trial, semaglutide's cardiovascular benefit was detectable across cardiovascular biomarkers and outcomes. For growth hormone secretagogue therapy, providers typically expect IGF-1 to increase toward the reference range, reflecting pituitary response; fasting glucose is monitored for any GH-related insulin resistance signal; and lean mass and visceral fat tracked clinically over months.

That principle — objective data before any clinical decision, and ongoing data to interpret response — is central to Superpower's approach to preventive health. Every therapy decision is more defensible when it starts with knowing where your biomarkers stand and continues with tracking how they respond over time.

Regulatory Status and How to Access Peptide Therapy

FDA approval status

As of April 2026, FDA-approved peptide medications in the therapeutic categories most commonly discussed in peptide therapy contexts include: semaglutide (Ozempic for type 2 diabetes, 2017, with an added January 2025 indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial; Wegovy for chronic weight management, 2021, with an added March 2024 indication to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; Rybelsus as an oral tablet for type 2 diabetes only, 2019, with a higher-dose oral semaglutide formulation for chronic weight management approved in April 2025); tirzepatide (Mounjaro for type 2 diabetes, 2022; Zepbound for chronic weight management, 2023, with an added December 2024 indication for moderate-to-severe obstructive sleep apnea in adults with obesity); tesamorelin (Egrifta for HIV-associated lipodystrophy); and insulin in multiple formulations for diabetes management. Details on semaglutide and tirzepatide are covered on their individual compound pages. Sermorelin, CJC-1295, and ipamorelin are not FDA-approved drugs; they are compounded by 503A pharmacies under the statutory framework described below (sermorelin acetate via its USP monograph; CJC-1295 and ipamorelin via other § 503A(b)(1)(A)(i) provisions where applicable). Following the February 2026 FDA reclassification actions, compounds including BPC-157 and TB-500 were classified as Category 2 bulk drug substances; their compounding under Section 503A is restricted pending further FDA review.

Compounding access and 503A

As of April 2026, licensed 503A compounding pharmacies can legally compound peptide bulk drug substances that either (a) are components of an FDA-approved drug, (b) are the subject of a USP or NF monograph, or (c) have been formally added to the 503A Bulks List by FDA rulemaking per FD&C Act § 503A(b)(1)(A)(i). Sermorelin acetate is compounded under this framework because it is the subject of a USP monograph. FDA has used interim "Category 1" and "Category 2" triage categories in evaluating nominations for the Bulks List; substances placed in Category 2 are those for which FDA has identified significant safety concerns and for which compounding is not recommended pending further review. A 2019 review by Mohiuddin, published in Innovations in Pharmacy, explained the legal and practice framework for 503A extemporaneous compounding (21 U.S.C. § 353a), including the patient-specific prescription requirement and the distinction from 503B outsourcing facilities. Compounds classified as biologics under BPCIA — including tesamorelin — cannot be lawfully compounded under 503A regardless of their approval status.

A note on compounded GLP-1 receptor agonists: during the 2022–2024 semaglutide and tirzepatide shortages, FDA exercised enforcement discretion allowing 503A and 503B pharmacies to compound these products. Both shortages were declared resolved (tirzepatide October 2024; semaglutide February 2025), and the corresponding enforcement-discretion windows closed in 2025. As of April 2026, 503A compounding of semaglutide or tirzepatide is permissible only under the narrow § 503A(b)(2) pathway requiring a patient-specific prescription with a documented clinically significant difference from the FDA-approved product — not as a routine alternative to branded supply.

Cost and insurance framing

FDA-approved peptide medications prescribed for their approved indications may qualify for insurance coverage with prior authorization; coverage policies vary by insurer, formulary, and clinical documentation. HSA and FSA accounts may cover prescribed peptide therapy depending on plan terms. Off-label and compounded formulations are typically not covered by insurance. Cost varies significantly across compounds, dosages, and whether branded or compounded formulations are used; no reliable generalization across the category is possible, and specific pricing claims become outdated before publication. The evaluation process through a licensed provider includes a clinical consultation and relevant baseline lab work as a precondition for prescribing.

How to Evaluate a Provider for Peptide Therapy

Access to peptide therapy through a qualified provider is what separates a clinically supervised approach from the unregulated gray market. A reputable provider should offer a clinical evaluation before prescribing, require relevant lab work, have a monitoring plan in place during therapy, and source compounds exclusively through licensed 503A compounding pharmacies where applicable. The 2026 narrative review by Mendias and Awan, published in Sports Medicine, found that unapproved peptides marketed direct-to-patient show favorable preclinical data but carry scarce human safety evidence, and emphasized that a rigorous supervised clinical approach is essential before starting any unapproved compound.

Questions to ask before starting with any provider:

• Do you require baseline lab work before prescribing? Which specific markers do you assess?
• How will you monitor my response, and how often will we review labs during therapy?
• Which compounding pharmacy do you use, and is it licensed in your state and operating under § 503A? Is it PCAB-accredited (a separate voluntary quality standard)?
• Is this compound FDA-approved for the indication you are prescribing it for, or is it off-label?
• What is the plan if I want to discontinue? Are there dose-tapering considerations?
• What compounds do you offer, and how do you determine which is appropriate for my situation?

Superpower's provider network includes licensed healthcare providers who evaluate candidacy and supervise prescribed therapy where clinically appropriate, with baseline lab work required before any peptide therapy is prescribed. For candidacy evaluation with a licensed provider for FDA-approved GLP-1 receptor agonists or compounded peptides available under Superpower's 503A pathway, visit Superpower's how-it-works page. Note: Superpower does not offer, prescribe, or dispense research-grade compounds (including BPC-157, TB-500), and Category 2 bulk drug substances cannot be lawfully compounded under § 503A.

IMPORTANT SAFETY INFORMATION

This article discusses peptide therapies as a category, including both FDA-approved medications and compounds not FDA-approved for human use. Not all compounds discussed carry the same evidence base, safety profile, or legal access pathway. Superpower Health does not prescribe medications. Whether a prescription is issued is the independent clinical judgment of the evaluating provider.

FDA-approved peptide medications are prescription drugs that must be obtained through a licensed healthcare provider and dispensed by a licensed pharmacy. Compounded peptides require a patient-specific prescription and must be obtained through a licensed 503A compounding pharmacy. As of April 2026, compounds including BPC-157 and TB-500 are classified as FDA Category 2 bulk drug substances; their compounding under Section 503A is restricted. Gray-market injectable products lack pharmaceutical-grade manufacturing oversight and carry contamination and dosing risks.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry FDA-labeled risks including: pancreatitis; cholelithiasis; thyroid C-cell effects (contraindicating use in patients with personal or family history of medullary thyroid carcinoma or MEN2); lean mass reduction requiring nutritional and exercise monitoring. Full prescribing information is available at dailymed.nlm.nih.gov.

Growth hormone secretagogue therapy carries risks including: IGF-1 elevation requiring monitoring; potential insulin resistance; fluid retention. These compounds are not FDA-approved drugs; their long-term safety profiles have not been established through adequate and well-controlled clinical trials outside narrow indications.

This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. Individual health conditions, current medications, and organ function affect both suitability and response to any peptide compound.

Disclaimer: This page discusses multiple compounds with varying FDA approval statuses. Some compounds mentioned may not be FDA-approved for human use. Superpower Health offers some but not all compounds discussed. See individual compound pages for specific availability and regulatory status. This content is for educational and informational purposes only.